Molecular mechanism of action at estrogen receptor α of a new clinically relevant antiestrogen (GW7604) related to tamoxifen

Endocrinology

Volumn 142, Issue 2, 2001, Pages 838-846

  Bentrem, D J ^a   Dardes, R C ^a   Liu, H ^a   Macgregor Schafer, J ^a   Zapf, J W ^a   Jordan, V C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1,2 DIPHENYL 1 BUTENYL)CINNAMIC ACID; 4 HYDROXYTAMOXIFEN; ANTIESTROGEN; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; GW 7604; RALOXIFENE; TAMOXIFEN; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ENDOMETRIUM CANCER; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0035103201     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.142.2.7932     Document Type: Article

References (38)

1. Third annual William L. McGuire Memorial Lecture. "Studies on the estrogen receptor in breast cancer"-20 years as a target for the treatment and prevention of cancer
2. Tamoxifen in the treatment of breast cancer
3. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
4. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial
5. Tamoxifen therapy for breast cancer and endometrial cancer risk
6. Response after withdrawal of tamoxifen and progestogens in advanced breast cancer
7. Pharmacokinetics, pharmacological and antitumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer
8. Selective oestrogen receptor modulation: Molecular pharmacology for the millennium
9. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) investigators
10. Tamoxifen, raloxifene, and the prevention of breast cancer
11. 3-[4-(1,2-diphenylbut-1-enyl)phenyl]acrylic acid: A non-steroidal estrogen with functional selectivity for bone over uterus in rats
12. Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone
13. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity
14. Evidence for the metabolic activation of non-steroidal antioestrogens: A study of structure-activity relationships
15. Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues
16. Comparative analyses of mechanistic differences among antiestrogens
17. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover
18. Importance of the alkylaminoethoxy side-chain for the estrogenic and antiestrogenic actions of tamoxifen and trioxifene in the immature rat uterus
19. Mammalian antifertility agents. 3. 1-Aryl-2-phenyl-1,2,3,4-tetrahydro-1- naphthols, 1-aryl-2phenyl-3,4-dihydronaphthalenes, and their derivatives
20. Molecular basis of agonism and antagonism in the oestrogen receptor
21. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen
22. The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain
23. A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog
24. Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor
25. The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor
26. The oestrogen-like effect of 4hydroxytamoxifen on induction of transforming growth factor alpha mRNA in MDA-MB-231 breast cancer cells stably expressing the oestrogen receptor
27. The interaction of raloxifene and the active metabolite of the antiestrogen EM-800 (SC 5705) with the human estrogen receptor
28. A simple, rapid, and sensitive DNA assay procedure
29. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines
30. Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor
31. Peptide antagonists of the human estrogen receptor
32. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351
33. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling
34. Effects of anti-estrogens on bone in castrated and intact female rats
35. Dual-energy x-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats
36. Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth
37. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice
38. Rapid development of tamoxifen stimulated mutant p53 breast tumors (T47D) in athymic mice